[The antitumor activity of DPD inhibitory-fluoropyrimidine (DIF) and non-DIF alone or in combination with paclitaxel against orthotopically implanted human breast cancer].
Nukatsuka
Mamoru
M
Cancer Research Laboratory, Taiho Pharmaceutical Co., Ltd.
Fujioka
Akio
A
Nakagawa
Fumio
F
Ohshimo
Hideyuki
H
Kitazato
Kenji
K
Fukushima
Masakazu
M
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D042943:Dihydrouracil Dehydrogenase (NADP); D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008813:Mice, Inbred ICR; D009368:Neoplasm Transplantation; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D017239:Paclitaxel / Q000008:administration & dosage*; D011743:Pyrimidines / Q000494:pharmacology*; D005641:Tegafur / Q000008:administration & dosage / Q000494:pharmacology; D014498:Uracil / Q000008:administration & dosage / Q000494:pharmacology
D000970:Antineoplastic Agents; D011743:Pyrimidines; D005467:Floxuridine; D005641:Tegafur; D014498:Uracil; C029269:5-fluoropyrimidine; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D017239:Paclitaxel; C025034:doxifluridine